Titre : Interleukine-9

Interleukine-9 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Data Collection
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interleukine-9 : Questions médicales les plus fréquentes", "headline": "Interleukine-9 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interleukine-9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-04", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interleukine-9" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Interleukines", "url": "https://questionsmedicales.fr/mesh/D007378", "about": { "@type": "MedicalCondition", "name": "Interleukines", "code": { "@type": "MedicalCode", "code": "D007378", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.465" } } }, "about": { "@type": "MedicalCondition", "name": "Interleukine-9", "alternateName": "Interleukin-9", "code": { "@type": "MedicalCode", "code": "D016906", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sushmita Chakraborty", "url": "https://questionsmedicales.fr/author/Sushmita%20Chakraborty", "affiliation": { "@type": "Organization", "name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India." } }, { "@type": "Person", "name": "Dipendra Kumar Mitra", "url": "https://questionsmedicales.fr/author/Dipendra%20Kumar%20Mitra", "affiliation": { "@type": "Organization", "name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India." } }, { "@type": "Person", "name": "Mattia Matasci", "url": "https://questionsmedicales.fr/author/Mattia%20Matasci", "affiliation": { "@type": "Organization", "name": "Philochem AG, CH-8112 Otelfingen, Switzerland." } }, { "@type": "Person", "name": "Dario Neri", "url": "https://questionsmedicales.fr/author/Dario%20Neri", "affiliation": { "@type": "Organization", "name": "Philochem AG, CH-8112 Otelfingen, Switzerland." } }, { "@type": "Person", "name": "Katharina F Kubatzky", "url": "https://questionsmedicales.fr/author/Katharina%20F%20Kubatzky", "affiliation": { "@type": "Organization", "name": "Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Impact of Using A Mixed Data Collection Modality on Statistical Inferences in Decentralized Clinical Trials.", "datePublished": "2022-05-24", "url": "https://questionsmedicales.fr/article/35608729", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s43441-022-00416-x" } }, { "@type": "ScholarlyArticle", "name": "A Data Collection Method for Mobile Wireless Sensor Networks Based on Improved Dragonfly Algorithm.", "datePublished": "2022-05-17", "url": "https://questionsmedicales.fr/article/35619765", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/4735687" } }, { "@type": "ScholarlyArticle", "name": "The DACRIN data project: A process for harmonising data collection for clinical research in alcohol and other drugs services in New South Wales.", "datePublished": "2023-04-24", "url": "https://questionsmedicales.fr/article/37095636", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/dar.13671" } }, { "@type": "ScholarlyArticle", "name": "Consistency as a Data Quality Measure for German Corona Consensus Items Mapped from National Pandemic Cohort Network Data Collections.", "datePublished": "2023-01-03", "url": "https://questionsmedicales.fr/article/36596462", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/a-2006-1086" } }, { "@type": "ScholarlyArticle", "name": "Essential data dimensions for prospective international data collection in older age bipolar disorder (OABD): Recommendations from the GAGE-BD group.", "datePublished": "2023-03-10", "url": "https://questionsmedicales.fr/article/36843436", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/bdi.13312" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Interleukines", "item": "https://questionsmedicales.fr/mesh/D007378" }, { "@type": "ListItem", "position": 6, "name": "Interleukine-9", "item": "https://questionsmedicales.fr/mesh/D016906" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interleukine-9 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interleukine-9", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interleukine-9", "description": "Comment mesurer l'interleukine-9 ?\nQuels tests sont utilisés pour le diagnostic ?\nL'IL-9 est-elle liée à des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-9 ?\nL'IL-9 peut-elle être un indicateur de gravité ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=6#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interleukine-9", "description": "Quels symptômes sont liés à l'IL-9 ?\nL'IL-9 provoque-t-elle des symptômes respiratoires ?\nY a-t-il des symptômes cutanés associés ?\nL'IL-9 est-elle liée à des symptômes gastro-intestinaux ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=6#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Interleukine-9", "description": "Comment prévenir les maladies liées à l'IL-9 ?\nY a-t-il des vaccins pour l'IL-9 ?\nL'éducation des patients est-elle importante ?\nLes changements alimentaires peuvent-ils aider ?\nLe contrôle de l'environnement est-il crucial ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=6#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interleukine-9", "description": "Comment traiter les niveaux élevés d'IL-9 ?\nY a-t-il des thérapies ciblées pour l'IL-9 ?\nLes corticostéroïdes affectent-ils l'IL-9 ?\nQuels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?\nL'immunothérapie aide-t-elle avec l'IL-9 ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=6#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interleukine-9", "description": "Quelles complications peuvent survenir avec l'IL-9 ?\nL'IL-9 peut-elle aggraver d'autres maladies ?\nY a-t-il des risques de surinfection ?\nDes complications pulmonaires sont-elles possibles ?\nL'IL-9 est-elle liée à des troubles cardiovasculaires ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=6#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interleukine-9", "description": "Quels sont les facteurs de risque pour l'IL-9 ?\nL'exposition à la pollution augmente-t-elle le risque ?\nLe tabagisme influence-t-il l'IL-9 ?\nLes infections respiratoires sont-elles un facteur ?\nLe stress a-t-il un impact sur l'IL-9 ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=6#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer l'interleukine-9 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-9 peut être mesurée par des tests ELISA dans le sérum ou les fluides biologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses de cytokines sont utilisés pour évaluer l'IL-9." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 est associée à des maladies comme l'asthme et certaines allergies." } }, { "@type": "Question", "name": "Quels biomarqueurs sont associés à l'IL-9 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-9 est souvent mesurée avec d'autres cytokines comme l'IL-4 et l'IL-5." } }, { "@type": "Question", "name": "L'IL-9 peut-elle être un indicateur de gravité ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés d'IL-9 peuvent indiquer une inflammation sévère." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'IL-9 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des réactions allergiques, de l'asthme et des inflammations." } }, { "@type": "Question", "name": "L'IL-9 provoque-t-elle des symptômes respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 est impliquée dans l'hyperréactivité bronchique et l'asthme." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent survenir dans des conditions allergiques liées à l'IL-9." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des symptômes gastro-intestinaux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut être impliquée dans des troubles gastro-intestinaux allergiques." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des difficultés respiratoires, des éruptions cutanées et des démangeaisons." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées à l'IL-9 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les allergènes et adopter un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des vaccins pour l'IL-9 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour cibler l'IL-9." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer les patients sur les déclencheurs allergiques est essentiel pour la prévention." } }, { "@type": "Question", "name": "Les changements alimentaires peuvent-ils aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut aider à réduire l'inflammation et les symptômes." } }, { "@type": "Question", "name": "Le contrôle de l'environnement est-il crucial ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, réduire l'exposition aux allergènes environnementaux est essentiel pour la prévention." } }, { "@type": "Question", "name": "Comment traiter les niveaux élevés d'IL-9 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements anti-inflammatoires et des antihistaminiques peuvent être utilisés." } }, { "@type": "Question", "name": "Y a-t-il des thérapies ciblées pour l'IL-9 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anticorps monoclonaux ciblant l'IL-9 sont en développement pour traiter l'asthme." } }, { "@type": "Question", "name": "Les corticostéroïdes affectent-ils l'IL-9 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent réduire les niveaux d'IL-9 et l'inflammation associée." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les bronchodilatateurs et les corticostéroïdes sont couramment prescrits." } }, { "@type": "Question", "name": "L'immunothérapie aide-t-elle avec l'IL-9 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'immunothérapie peut aider à moduler la réponse immunitaire liée à l'IL-9." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'IL-9 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des exacerbations d'asthme et des réactions allergiques sévères." } }, { "@type": "Question", "name": "L'IL-9 peut-elle aggraver d'autres maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut exacerber des maladies auto-immunes et inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des risques de surinfection ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des niveaux élevés d'IL-9 peuvent être à risque de surinfections." } }, { "@type": "Question", "name": "Des complications pulmonaires sont-elles possibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut contribuer à des complications pulmonaires comme la fibrose." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des troubles cardiovasculaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre l'IL-9 et des troubles cardiovasculaires, mais c'est encore à étudier." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'IL-9 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux d'allergies et d'asthme augmentent le risque d'IL-9 élevée." } }, { "@type": "Question", "name": "L'exposition à la pollution augmente-t-elle le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la pollution de l'air est un facteur de risque connu pour les maladies liées à l'IL-9." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il l'IL-9 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux d'IL-9 et aggraver les symptômes respiratoires." } }, { "@type": "Question", "name": "Les infections respiratoires sont-elles un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections respiratoires peuvent déclencher une réponse immunitaire impliquant l'IL-9." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur l'IL-9 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les symptômes et augmenter les niveaux d'IL-9." } } ] } ] }

Sources (10000 au total)

Impact of Using A Mixed Data Collection Modality on Statistical Inferences in Decentralized Clinical Trials.

Decentralized clinical trials offer the promise of reduced patient burden, faster and more diverse recruitment, and have received regulatory support during the COVID-19 pandemic. However, lack of data... In this article we evaluate the estimation and statistical inference for three scenarios: (1) all onsite measurements, (2) a mixture of onsite and decentralized measurements, and (3) all decentralized... In the mixed modality setting, simulation studies showed that the estimation and inference for the key time points with onsite measurements have good properties and are not impacted by the additional ... Mixed modality trials can help achieve the benefits of decentralized clinical trials by reducing the number of onsite visits with little impact on statistical inferences for various estimands, compare...

The DACRIN data project: A process for harmonising data collection for clinical research in alcohol and other drugs services in New South Wales.

Standardised data collection processes allow for harmonisation and comparison of data across different studies and services. This project aimed to develop a 'core dataset' to serve as the default coll... A working group was established, comprising clinicians, researchers, data managers and consumers from public sector and non-government organisation AOD services in the NSW Drug and Alcohol Clinical Re... There were 20-40 attendees at each meeting. An initial consensus criterion of having received >70% of the vote was established. Given the difficulty in reaching consensus for most items, subsequently,... This important process received considerable interest and buy-in across the NSW AOD sector. Ample opportunity for discussion and voting was provided for the three domains of interest, allowing partici...

Consistency as a Data Quality Measure for German Corona Consensus Items Mapped from National Pandemic Cohort Network Data Collections.

As a national effort to better understand the current pandemic, three cohorts collect sociodemographic and clinical data from coronavirus disease 2019 (COVID-19) patients from different target populat... The goal of this work is to assure high consistency of research data mapped to the GECCO data model. In particular, it aims at identifying contradictions within interdependent GECCO data items of the ... All suitable data items from each of the three NAPKON cohorts are mapped to the GECCO items. A consistency assessment tool (dqGecco) is implemented, following the design of an existing quality assessm... Our consistency assessment tool helped in correcting the mapping procedure and reveals remaining contradictory value combinations within COVID-19 symptoms, vital signs, and COVID-19 severity. Consiste... An efficient and portable tool capable of discovering inconsistencies in the COVID-19 domain has been developed and applied to three different cohorts. As the GECCO dataset is employed in different pl...

Essential data dimensions for prospective international data collection in older age bipolar disorder (OABD): Recommendations from the GAGE-BD group.

By 2030, over 50% of individuals living with bipolar disorder (BD) are expected to be aged ≥50 years. However, older age bipolar disorder (OABD) remains understudied. There are limited large-scale pro... We developed initial recommendations for the essential dimensions for OABD data collection, based on (1) a systematic review of measures used in OABD studies, (2) a Delphi consensus of international O... We identified 15 key dimensions and variables within each that are relevant for the investigation of OABD: (1) demographics, (2) core symptoms of depression and (3) mania, (4) cognition screening and ... The essential data dimensions we present should be of use to guide future international data collection in OABD and clinical practice. In the longer term, we aim to establish a prospective consortium ...

Core Data Elements for Pregnancy Pharmacovigilance Studies Using Primary Source Data Collection Methods: Recommendations from the IMI ConcePTION Project.

The risks and benefits of medication use in pregnancy are typically established through post-marketing observational studies. As there is currently no standardised or systematic approach to the post-m... This CDE reference framework was developed within the Innovative Medicines Initiative (IMI) ConcePTION project by experts in pharmacovigilance, pharmacoepidemiology, medical statistics, risk-benefit c... The finalised listing of CDEs comprises 98 individual data elements, arranged into 14 tables of related fields. These data elements are openly available on the European Network of Teratology Informati... With this set of recommendations, we aim to standardise PregPV primary source data collection processes to improve the speed at which high-quality evidence-based statements can be provided about the s...

Wearable alcohol monitors for alcohol use data collection among college students: Feasibility and acceptability.

We assessed the feasibility and acceptability of using BACtrack Skyn wearable alcohol monitors for alcohol research in a college student population.... We enrolled n = 5 (Sample 1) and n = 84 (Sample 2) Indiana University undergraduate students to wear BACtrack Skyn devices continuously over a 5-day to 7-day study period. We assessed feasibility in b... All participants were able to successfully use the alcohol monitors, producing a total of 11,504 h of TAC data. TAC data were produced on 567 days of the 602 total possible days of data collection. Th... The high feasibility and acceptability we observed underscore the promise of using BACtrack Skyn wearable alcohol monitors to improve our understanding of alcohol consumption among college students, a...

Five tips for conducting remote qualitative data collection in COVID times: theoretical and pragmatic considerations.

To provide five methodological and pragmatic tips for conducting remote qualitative data collection during the context of the COVID-19 pandemic.... The tips presented in this article are drawn from insights of our own experiences as researchers conducting remote qualitative research and from the evidence from the literature on qualitative methods... Five tips are provided: 1) Pay attention to ethical issues; 2) Identify and select potential participants; 3) Choose the type of remote interview; 4) Be prepared to conduct the remote interview; and 5... Despite the challenges in conducting remote data collection, strengths are also acknowledged and our experience has shown that it is feasible to recruit and interview participants remotely. The discus...